Last reviewed · How we verify
Ertugliflozin 5 mg, 15mg
Ertugliflozin, marketed by Getz Pharma in 5 mg and 15 mg formulations, holds a position in the competitive diabetes market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and mechanism of action, which differentiates it from other antidiabetic agents. The primary risk is the potential increase in competition as the patent expiration approaches, which could impact revenue and market share.
At a glance
| Generic name | Ertugliflozin 5 mg, 15mg |
|---|---|
| Sponsor | Getz Pharma |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure (PHASE2)
- Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ertugliflozin 5 mg, 15mg CI brief — competitive landscape report
- Ertugliflozin 5 mg, 15mg updates RSS · CI watch RSS
- Getz Pharma portfolio CI